阿莫西林与阿莫西林-克拉维酸治疗社区获得性肺炎的系统综述与荟萃分析
比较阿莫西林或其他抗生素在临床缓解和临床失败上均无显著差异证据，但因试验数量少和异质性大，结论尚不明确。
要点
- 阿莫西林与其他抗生素临床缓解比较无差异证据（汇总OR 0.88，95%CI 0.56-1.38）。
- 阿莫西林-克拉维酸与其他抗生素临床缓解比较无差异证据（OR 0.89，95%CI 0.76-1.04）。
- 阿莫西林与其他抗生素临床失败差异不明确（OR 0.76，95%CI 0.55-1.06）。
核心结论
- 当前证据尚不明确阿莫西林或阿莫西林-克拉维酸与其他抗生素之间、或二者之间治疗社区获得性肺炎是否存在差异。
研究设计与样本
- 系统综述与荟萃分析，检索PubMed、Cochrane Library、Web of Science和Ovid-MEDLINER至2024年7月16日，无语言限制。
- 纳入比较阿莫西林或阿莫西林-克拉维酸与其他抗生素或安慰剂的随机对照试验，主要结局为临床缓解或临床失败。
主要发现
- 阿莫西林与其他抗生素比较临床缓解无差异证据（15项试验；汇总OR 0.88；95%CI 0.56-1.38；>1有利于阿莫西林）。
- 阿莫西林-克拉维酸与其他抗生素比较临床缓解无差异证据（17项；OR 0.89；95%CI 0.76-1.04）。
- 阿莫西林与其他抗生素临床失败差异不明确，无法排除临床重要获益或危害（8项；OR 0.76；95%CI 0.55-1.06；1有利于阿莫西林-克拉维酸）。
临床怎么用
- 现有证据不支持阿莫西林或阿莫西林-克拉维酸在社区获得性肺炎治疗中优于其他抗生素。
- 临床决策需结合当地耐药情况和患者个体因素，因比较药物异质性大。
局限性
- 试验数量少且不同研究设置的比较药物存在显著异质性，导致证据不明确。
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
原文
BMJ Open. 2026 May 7;16(5):e112219. doi: 10.1136/bmjopen-2025-112219. ABSTRACT OBJECTIVES: The aim of this study is to evaluate existing evidence on the effectiveness of amoxicillin and amoxicillin-clavulanate for community-acquired pneumonia in children and adults. DESIGN: Systematic review and meta-analysis. DATA SOURCES: PubMed, Cochrane Library, Web of Science and Ovid-MEDLINER were searched with no language restrictions through 16 July 2024. ELIGIBILITY CRITERIA: We included studies comparing the effectiveness of amoxicillin or amoxicillin-clavulanate versus other antibiotics or placebo. DATA EXTRACTION AND SYNTHESIS: Only randomised controlled trials comparing amoxicillin or amoxicillin-clavulanate with another antibiotic or placebo with a primary outcome of clinical resolution or clinical failure were eligible for our review. We used random-effects and fixed-effects logistic regression models to estimate the pooled treatment effect size. Heterogeneity of the studies was evaluated using the τ statistic. We performed an unplanned frequentist random-effects network meta-analysis for the indirect comparison between amoxicillin and amoxicillin-clavulanate. The revised Cochrane risk of bias tool for randomised trials was used to assess and categorise studies into low risk of bias, some concerns or high risk of bias. RESULTS: We extracted data from 44 studies including 45 400 patients. We found no evidence of a differential effect on clinical resolution when comparing amoxicillin with other antibiotics (n=15 trials; pooled OR 0.88; 95% CI 0.56 to 1.38, where >1 favours amoxicillin) or amoxicillin-clavulanate with other antibiotics (n=17; OR 0.89; 95% CI 0.76 to 1.04). Similarly, evidence of difference in clinical failure between amoxicillin and other antibiotics was unclear and unable to rule out clinically important benefits or harms (n=8; OR 0.76; 95% CI 0.55 to 1.06, where 1 favours amoxicillin-clavulanate). Sixty-three per cent and 29% of amoxicillin and amoxicillin-clavulanate studies, respectively, had low risk of bias according to the Cochrane risk of bias tool for randomised trials. CONCLUSIONS: Current evidence is unclear as to whether amoxicillin or amoxicillin-clavulanate differs from other antibiotics, or from each other, in the treatment of community-acquired pneumonia, owing to the small number of trials and substantial heterogeneity in comparators used across study settings. PROSPERO REGISTRATION NUMBER: CRD42024568554. PMID: 42097647 | PMC:
引用
- PubMed 高证据 · 肺炎：Effectiveness of amoxicillin and amoxicillin-clavulanate for the treatment of community-acquired pneumonia in adults and children: a systematic review and meta-analysis
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。